Effect of rapamycin nanoparticles in an animal model of primary biliary cholangitis

Figure 3 Nanoparticles encapsulating rapamycin treatment decreased serum anti-mitochondrial antibodies levels and inhibited the expression of cytokines. A: Levels of anti-mitochondrial antibodies at 4 weeks, 8 weeks and 12 weeks in primary biliary cholangitis (PBC) mice treated with nanoparticles encapsulating rapamycin and in mice in the control group; B: Comparative serum profiling of interferon gamma between control and treated PBC mice; C: Comparative serum levels of tumor necrosis factor α between the control and treatment group (^aP < 0.05). AMA: Anti-mitochondrial antibodies; IFN-γ: Interferon gamma; TNF-α: Tumor necrosis factor α.